H.C. Wainwright analyst Ed Arce lowered the firm’s price target on Travere Therapeutics to $18 from $23 and keeps a Buy rating on the shares after the company announced a voluntary enrollment pause for the Phase 3 HARMONY study of pegtibatinase for the treatment of classical homocystinuria. While the unexpected enrollment pause represents a meaningful delay to pegtibatinase’s time to market, the pause was not due to any safety and efficacy issue with pegtibatinase, and the manufacturing issue seems to be fixable, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Closing Bell Movers: Costco slips 1% as Q4 revenue misses estimates
- Travere annnounces voluntary pause of nnrollment in the Phase 3 HARMONY study
- Travere Therapeutics price target raised to $23 from $20 at JPMorgan
- Travere Therapeutics price target raised to $23 from $18 at Canaccord
- Travere upgraded to Buy at Guggenheim after IgAN approval, ahead of FSGS updates
Questions or Comments about the article? Write to editor@tipranks.com